Erratum to Acute Effects of Very-Low-Protein Diet on FGF23 Levels: A Randomized Study (Clin J Am Soc Nephrol, (2012), 7, (581-587), (doi:10.2215/CJN.07640711));Acute effects of very-low-protein diet on FGF23 levels: A randomized study

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 4, 2012, Pages 581-587

  di Iorio, Biagio ^a   di Micco, Lucia ^a   Torraca, Serena ^a   Sirico, Maria Luisa ^a   Russo, Luigi ^b   Pota, Andrea ^a   Mirenghi, Francesco ^a   Russo, Domenico ^b  

^a A Landolfi Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; PHOSPHORUS;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN INTAKE; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 84859524237     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04720512     Document Type: Erratum

References (51)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
2. Schmitt CP, Odenwald T, Ritz E: Calcium, calcium regulatory hormones, and calcimimetics: Impact on cardiovascular mortality. J Am Soc Nephrol 17[Suppl 2]: S78-S80, 2006
3. Lafage-Proust MH: Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 77: 390-392, 2010
4. Ritz E, Gross ML, Dikow R: Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int Suppl 99: S66-S70, 2005
5. Berndt TJ, Schiavi S, Kumar R: Phosphatonins and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289: F1170-F1182, 2005
6. Prié D, Urena Torres P, Friedlander G: Latest findings in phosphate homeostasis. Kidney Int 75: 882-889, 2009
7. Komaba H, Fukagawa M: FGF23-parathyroid interaction: Implications in chronic kidney disease. Kidney Int 77: 292-298, 2010
8. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
9. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
10. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
11. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24: 948-955, 2009
12. Juppner H: Phosphate and FGF-23. Kidney Int Suppl 121:S24-S27, 2011
13. Dwyer J, Kenler SR: Assessment of nutritional status in renal disease. In: Nutrition and the Kidney, 2nd Ed., edited by Mitch WE, Klahr S, Little, Brown and Company, 1993, pp 61-96
14. Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, Rubino R, Conte G: Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 64: 1822-1828, 2003
15. Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, Catapano F, Cristofano C, Scalfi L, Conte G; ERIKA Study-group: Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 71: 245-251, 2007
16. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, Kovesdy CP, Bross R, Shinaberger CS, Noori N, Hirschberg R, Benner D, Nissenson AR, Kopple JD: Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 519-530, 2010
17. Benini O, D'Alessandro C, Gianfaldoni D, Cupisti A: Extraphosphate load from food additives in commonly eaten foods: A real and insidious danger for renal patients. J Ren Nutr 21: 303-308, 2011
18. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002
19. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ: Sensitivity of fibroblast growth factor 23measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91: 2055-2061, 2006
20. Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM, Blankenstein MA: Determination of fibroblast growth factor 23. Ann Clin Biochem 46: 338-340, 2009
21. Walton RJ, Bijvoet OL: Nomogram for derivation of renal threshold phosphate concentration. Lancet 2: 309-310, 1975
22. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
23. Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: TheHeart and Soul study. Nephrol Dial Transplant 5: 993-997, 2010
24. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
25. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
26. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, KuypersD, Vanderschueren D, Vanrenterghem Y: Fibroblast growth factor-23 in early chronic kidney disease: Additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 5: 1268-1276, 2010
27. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA: Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 106: 854-859, 2002
28. Gutié rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
29. Hruska K, Mathew S, Lund R, Fang Y, Suatani T: Cardiovascular risk factors in chronic kidney disease: Does phosphate qualify? Kidney Int Suppl 121: S9-S13, 2011
30. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551, 2009
31. Oliveira RB, Cancela ALE, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
32. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, Wolf M: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26: 584-591, 2011
33. Shigematsu T, Negi S; the COLC Research Group: Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study) [published online ahead of print July 19, 2011]. Nephrol Dial Transplant doi:10.1093/ndt/gfr388
34. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, YenicescuM, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 59: 177-185, 2012
35. Savica V, Calo LA, Monardo P, Caldarera R, Cavaleri A, Santoro D, Muraca U, Mallamace A, Bellinghieri G: High phosphate content beverages in dialysis patients: Relevance for hyperphosphatemia and cardiovascular risk. Nutr Metab Cardiovasc Dis 18: e39-e40, 2008
36. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA: The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 19: 1092-1105, 2008
37. Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR: Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 301: 629-635, 2009
38. Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 3144-3149, 2006
39. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
40. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin EndocrinolMetab 90: 1519-1524, 2005
41. Portale AA, Booth BE, Halloran BP, Morris RC Jr: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 1580-1589, 1984
42. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR: Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J AmSoc Nephrol 6: 257-264, 2011
43. Gutié rrez OM, Wolf M, Taylor EN: Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6: 2871-2878, 2011
44. Gutiérrez OM: Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 5: 1710-1716, 2010
45. Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Avdin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A: Fibroblast growth factor 23 and fetuin A are independent predicotors for the coronary artery disease extend in mild CKD. Clin J Am Soc Nephrol 5: 1780-1786, 2010
46. Larsson TE: The role of FGF-23 in CKD-MBD and cardiovascular disease: Friend or foe? Nephrol Dial Transplant 25: 1376-1381, 2010
47. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heiner GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25: 3983-3989, 2010
48. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yemicesu M, Zoccali C: FGF23 and vascular disfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685, 2010
49. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796, 2009
50. Isakova T, Xie H, YangW, Xie D, Anderson AH, Scialla J, Wahl P, Gutié rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
51. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011